Erika Hamilton, Chair of Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“What will we see at today’s ASCO25 Breast Cancer rapid oral?
Hall D2, 2:45-4:15pm CST
– TDXd Drug rechallenge after ILD
– sac-TMT 1st L TNBC – OptiTROP-Br05
– AI for pathologic assessment of HER-2
– Kat-6 inhibitor for ER+ MBC
– PI3 (gedatolisib) + trastuzumab for HER-2
– 2 abstracts around efficacy in brain metastasis
…and more.”
More posts featuring ASCO 2025.
